Kit ELISA ShhN sandwich (SHH) (human): quantitative determination of HHH in serum, plasma or cell culture medium. The test recognizes only the natural and recombinant forms of Hu SHH.
Kit ELISA ShhN sandwich (SHH) (human): quantitative determination of HHH in serum, plasma or cell culture medium. The test recognizes only the natural and recombinant forms of Hu SHH.
Method principle: This ELISA solid phase sandwich test (immuno-enzymatic dose) measures the amount of target bound between a pair of matched antibodies. A specific target antibody is pre-adsorbed into the wells of the supplied microplate. Samples, standards or controls are added to these wells and bind to immobilized antibodies (capture antibodies). The sandwich is formed by adding the second antibody (detection antibody), then a substrate solution reacts with the enzyme-antibodies-target complex to produce a measurable signal. The intensity of this signal is directly proportional to the concentration of the target present in the original sample.
Rigorous validation: Each batch manufactured from this ELISA kit is checked for criteria such as sensitivity, specificity, accuracy and reproducibility from one batch to another (see the package leaflet for more information on validation).
Sonic Hedgehog (SHH), which is expressed only during embryogenesis, plays a key role in early embryo modelling. It was involved as a key inductive signal in the modelling of the ventral neural tube, the anterior-posterior axis of the limbs and ventral somites. Among the three human proteins with a similar sequence and functionality with Drosophile Sonic Hedgehog protein, this protein is the most similar. The protein is secreted as a precursor that is cleaved by autocatalytic means, the N-terminal part being soluble and containing signaling activity while the C-terminal part is involved in the treatment of precursors. Furthermore, the C-terminal product covalently fixes a cholesterol fraction to the N-terminal product, limiting the N-terminal product to the cell surface and preventing free distribution throughout the developing embryo. Anomaly of this protein or its signaling pathway is a cause of holoprosencephaly (HPE), a disease resulting from a lack of median cleavage of the anterior encephalus into the right and left hemispheres during embryonic development. HPE is manifested by facial deformations. In addition, mutations in this gene or its signalling pathway are thought to be responsible for VACTERL syndrome, which is characterized by vertebral abnormalities, anal atresia, tracheo-esophageal fistula with estretic oesophageal arousal, radial and renal dysplasia, cardiac abnormalities and limb abnormalities.
Sensitivity
Sensitivity of dosage: 8 pg/ml.
Measurement range
Dose range: 40.96 pg/ml to 10.000 pg/ml.
Duration of dosing
Total dosage duration: 4 hours 45 min.
Samples
Sample type: Plasma, Serum, Surnatant (plasma volume, 50 μl; serum, 50 μl; supernatant, 100 μl).
Technical specifications
| General |
| Brand | Invitrogen |
| Supplier ref. (Fisher Scientific) | 17155559 |
| Specifications |
| Accession number | Q15465 |
| Dose range | 40.96 pg/ml to 10.000 pg/ml |
| Sensitivity of the dosage | 8 pg/ml |
| Calibration range | 8 pg/ml to 10.000 pg/ml |
| Dose | ELISA solid-phase sandwich |
| Conjugate | Biotin |
| Product type | Kit ELISA |
| Protein family | Proteases, peptidases & inhibitors |
| Type of sample | Plasma, Serum, Surnatant |
| Specificity | This ELISA kit shows no cross-reactivity with the following tested cytokines: human angiogenin, BDNF, BLC, ENA-78, FGF- 4, IL-1 alpha, IL-1 beta, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-11, IL-12 p70, IL-12 p40, IL-13, IL-15, IL-309, IP-10, G-CSF, GM-CSF, IFN-gamma, leptin ( |
| Sufficient for | 5 x 96 dosages |
| Target species | Human |
| For use with (application) | ELISA, protein dosage, protein biology, cancerology, immunology, neuroscience, neurobiology, protein detection, protein analyses |
| For use with (equipment) | Colorimetric microplate reader |
| Genetic identification (Enter) | 6469 |
| Gene symbol(s) | HHG1,HLP3,HPE3,MCOPCB5,SMMCI,TPT,TPTPS |
| Coefficient of inter-dose variation | <12% |
| Coefficient of intra-dose variation | <10% |
| Contents of kits | Discontinuation solution, Biotinylated detection antibody, Wash pad, Stalcon, Adhesive plate covers, Chromogen, 96-well pre-coated plates, Dosing diluent concentrate, SAV-HRP |
| Marker or dye | HRP |
| Quantity | 5 x 96 tests |
| Regulatory status | RUO |
| Research disciplines | Development |
| Synonym | tcag7.582, HHG1, HLP3, HPE3, MCOPCB5, SMMCI, TPT, TPTPS |
| Target | Human |
| Test time | 1 hour 20 minutes. |
| Physical characteristics |
| Volume of sample | Plasma, 50 μl; serum, 50 μl; supernatant, 100 μl |
| Storage and shipping |
| Storage conditions | 2°C to 8°C |
| Total duration of dosing | 4:45 a.m. |
Origin and customs
| Manufacturer ref. | EHSHHX5 |
|---|
| Country of origin | United States |
|---|
A question or a specific configuration?
Contact us for a quote.